MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2023-24)
- Udyam number
- UDYAM-MH-26-0008247
Market Cap
₹96.08 Cr
CHCL · BSE
Share Price
₹39.19
+1.98% today
Revenue
₹28.30 Cr
FY 2025-26 · -8.1% YoY
EBITDA
−₹20.22 Cr
Margin -71.5%
Net Profit
−₹10.06 Cr
FY 2025-26 · +26.7% YoY
Authorised capital
₹25 Cr
Registered with MCA
Paid-up capital
₹25 Cr
Issued & subscribed
Satisfied charges
₹60.53 Cr
No open charges
About Cian Healthcare Limited
Data last updated:
Cian Healthcare Limited is a public limited company based in Pune, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 07 January 2003 and has been in existence for over 23 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN L24233PN2003PLC017563. Its GSTIN is 05AACCC5027C1ZB (Uttarakhand). The company holds 6 GST registrations, of which 2 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 542678.
The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹25 Cr. It was formerly known as Cian Healthcare Private Limited. It is led by directors including Rajesh Jain (Managing Director) and Manish Goswami.
Its last annual general meeting (AGM) was held on 17 December 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Pune, Maharashtra.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹28.3 Cr, a decline of 8.1% compared to the previous year. For the same year it recorded a net loss of ₹10.06 Cr (net margin -35.5%) and EBITDA of -₹20.22 Cr (EBITDA margin -71.4%). The net worth stands at ₹8.54 Cr (down 73.6% YoY). Total assets are valued at ₹40.26 Cr (down 54.9% YoY).
The company has about 117 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 3 brands: American Physician Institute, Cian Health Care and Mind Solutions. As per MCA filings, the company has satisfied charges of ₹60.53 Cr on record. Court records list 203 cases involving the company, including 67 filed by the company and 136 filed against it; 105 cases are pending. The company has 47 deals on record (46 market trades, 1 ipo); the latest was in December 2025. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Thinq Pharma-Cro Limited with revenue of ₹62.89 Cr. The company has 22 MSME Form 1 returns on record between 2018 and 2024, listing 5,121 overdue payments to 198 micro and small suppliers.
Cian Healthcare Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-26-0008247). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cian.co.
Company details
CIN L24233PN2003PLC017563
Registration Number 017563
Incorporation Date 07 January 2003
ROC Pune
Listing Status Listed - Listed on BSE (542678)
Company Status Active
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-26-0008247
CIN history
Cian Healthcare has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24233PN2003PLC017563, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24233PN2003PLC017563 | Current |
| U24233PN2003PLC017563 | Previous |
| U24233PN2003PTC017563 | Previous |
Recognitions & Rankings of Cian Healthcare
Contact details
Cian Healthcare Limited's registered office is in Pune, Maharashtra. Its website is cian.co. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressUnit – 01 Konark Icon 3rd Flr. Sn – 134, Cc No – 4979 Hn – 1D/2 Nr. Magarpatta, Pune, Maharashtra, India – 411028
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Cian Healthcare Limited, buy the company report.
Comprehensive company report
Cian Healthcare Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Cian Healthcare operates multiple associated brands including American Physician Institute, Cian Health Care, and Mind Solutions. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Offers board review courses, CME programs, and career resources for physicians. | americanphysician.com | |
| Pharmaceuticals, OTCs, supplements, and veterinary products are manufactured. | cian.co | |
| Brain-computer interface systems for mind-machine interactions are developed. | mindsolutionscorp.com |
Business activity
The main business activity of Cian Healthcare is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Cian Healthcare Limited, buy the company report.
Financials of Cian Healthcare Limited
FY 2025-26 filings availableCian Healthcare Limited reported revenue of ₹28.3 Cr (down 8.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹28.30 Cr
-8.1% YoY
EBITDA
−₹20.22 Cr
-7.8% YoY
Profit After Tax
−₹10.06 Cr
+26.7% YoY
Net Worth
₹8.54 Cr
-73.6% YoY
Total Assets
₹40.26 Cr
-54.9% YoY
Total Debt
₹28.66 Cr
-47.9% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 28.30 | 30.80 | 61.70 | 68.59 | 77.87 | 73.73 | 57.09 |
| Revenue growth | -8.1% | -50.1% | -10.1% | -11.9% | +5.6% | +29.2% | - |
| EBITDA | (20.22) | (18.75) | 11.08 | 12.99 | 4.29 | 11.78 | 7.28 |
| EBITDA margin | -71.5% | -60.9% | +18.0% | +18.9% | +5.5% | +16.0% | +12.8% |
| Profit before tax | (23.18) | (25.99) | 0.05 | 1.99 | (5.99) | 0.69 | (3.53) |
| Net profit | (10.06) | (13.73) | 0.85 | 1.94 | (5.45) | 0.08 | (3.73) |
| Net profit margin | -35.6% | -44.6% | +1.4% | +2.8% | -7.0% | +0.1% | -6.5% |
| EPS (₹) | (9.32) | (10.39) | 0.34 | 0.81 | (2.21) | 0.02 | (1.62) |
| Balance sheet | |||||||
| Total assets | 40.26 | 89.17 | 123 | 126 | 120 | 131 | 133 |
| Net worth | 8.54 | 32.36 | 58.34 | 57.49 | 55.46 | 58.24 | 58.19 |
| Total debt | 28.66 | 54.99 | 55.69 | 60.81 | 63.05 | 70.73 | 72.94 |
| Cash & bank | 1.20 | 17.77 | 1.19 | 1.33 | 1.34 | 2.32 | 3.45 |
| Net working capital | 2.22 | 4.48 | 33.82 | 40.41 | 34.42 | 38.67 | 32.85 |
| Cash flow | |||||||
| Cash from operations | (1.47) | 20.75 | 11.76 | 4.84 | 8.58 | 5.93 | (7.31) |
| Cash from investing | 13.27 | (0.25) | (1.46) | 2.55 | 1.40 | 2.71 | (27.44) |
| Cash from financing | (28.37) | (3.92) | (10.44) | (7.41) | (10.96) | (9.78) | 35.78 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 28.30 | 30.88 | 58.75 | 67.56 | 64.10 | 72.38 | 57.05 |
| Revenue growth | -8.4% | -47.4% | -13.0% | +5.4% | -11.4% | +26.9% | - |
| EBITDA | (19.73) | (15.15) | 7.57 | 8.98 | 4.96 | 9.31 | 7.63 |
| EBITDA margin | -69.7% | -49.1% | +12.9% | +13.3% | +7.7% | +12.9% | +13.4% |
| Profit before tax | (20.91) | (19.67) | 0.02 | 1.20 | (2.38) | 0.67 | 0.08 |
| Net profit | (7.79) | (7.41) | 0.40 | 1.05 | (2.21) | 0.41 | (0.14) |
| Net profit margin | -27.5% | -24.0% | +0.7% | +1.6% | -3.5% | +0.6% | -0.3% |
| EPS (₹) | (8.41) | (7.86) | 0.16 | 0.43 | (0.91) | 0.14 | (0.03) |
| Balance sheet | |||||||
| Total assets | 37.13 | 83.77 | 112 | 111 | 105 | 111 | 112 |
| Net worth | 20.61 | 42.16 | 61.82 | 61.43 | 60.35 | 59.87 | 59.55 |
| Total debt | 13.67 | 39.99 | 41.01 | 42.71 | 43.08 | 49.30 | 51.22 |
| Cash & bank | 1.13 | 17.66 | 0.73 | 1.13 | 1.22 | 2.21 | 3.02 |
| Net working capital | 7.34 | 8.99 | 34.32 | 40.07 | 35.01 | 35.55 | 30.58 |
| Cash flow | |||||||
| Cash from operations | (1.53) | 20.66 | 6.94 | 2.15 | 5.51 | 5.46 | (9.24) |
| Cash from investing | 13.36 | (0.27) | (0.93) | (1.08) | (3.85) | (1.20) | (25.16) |
| Cash from financing | (28.36) | (3.46) | (6.41) | (1.17) | (2.65) | (5.07) | 35.09 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 12 Nov 2026
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 28.30 | 30.80 | 61.70 | 68.59 | 77.87 | 73.73 | 57.09 |
| Revenue growth | -8.1% | -50.1% | -10.1% | -11.9% | +5.6% | +29.2% | - |
| Other income | 1.17 | 0.19 | 0.44 | 0.73 | 0.54 | 0.28 | 0.86 |
| Total expenses | 48.52 | 49.55 | 50.62 | 55.60 | 73.58 | 61.95 | 49.81 |
| Employee cost | 0.00 | 6.87 | 8.12 | 8.86 | 9.37 | 6.68 | 4.04 |
| EBITDA | (20.22) | (18.75) | 11.08 | 12.99 | 4.29 | 11.78 | 7.28 |
| EBITDA margin | -71.5% | -60.9% | +18.0% | +18.9% | +5.5% | +16.0% | +12.8% |
| Depreciation | 3.91 | 4.39 | 5.47 | 5.43 | 4.27 | 3.45 | 4.45 |
| Interest | 0.22 | 3.04 | 6.00 | 6.30 | 6.55 | 7.92 | 7.22 |
| Profit before tax | (23.18) | (25.99) | 0.05 | 1.99 | (5.99) | 0.69 | (3.53) |
| Tax | 0.11 | (0.02) | (0.80) | (0.04) | (0.47) | 0.63 | 0.26 |
| Net profit | (10.06) | (13.73) | 0.85 | 1.94 | (5.45) | 0.08 | (3.73) |
| Net profit margin | -35.6% | -44.6% | +1.4% | +2.8% | -7.0% | +0.1% | -6.5% |
| EPS (₹) | (9.32) | (10.39) | 0.34 | 0.81 | (2.21) | 0.02 | (1.62) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 23.36 | 23.36 |
| Reserves & surplus | (16.46) | 7.36 | 33.34 | 32.49 | 30.46 | 34.88 | 34.83 |
| Shareholders' funds (net worth) | 8.54 | 32.36 | 58.34 | 57.49 | 55.46 | 58.24 | 58.19 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 8.50 | 41.22 | 42.14 | 49.19 | 50.18 | 57.29 | 58.41 |
| Unsecured loans | 20.16 | 13.77 | 13.55 | 11.62 | 12.87 | 13.44 | 14.53 |
| Total debt | 28.66 | 54.99 | 55.69 | 60.81 | 63.05 | 70.73 | 72.94 |
| Total liabilities | 40.26 | 89.17 | 123 | 126 | 120 | 131 | 133 |
| Assets | |||||||
| Gross block | 70.57 | 69.74 | 69.70 | 70.14 | 69.71 | 52.39 | 51.23 |
| Net block | 31.83 | 34.93 | 39.28 | 44.58 | 49.58 | 36.54 | 39.43 |
| Capital work in progress | 6.16 | 15.07 | 14.70 | 13.89 | 13.00 | 25.93 | 25.03 |
| Investments | 0.10 | 4.89 | 4.89 | 4.89 | 4.89 | 4.89 | 4.89 |
| Inventories | 5.05 | 26.08 | 40.93 | 36.64 | 39.37 | 30.73 | 19.72 |
| Sundry debtors | 12.64 | 17.39 | 20.48 | 26.23 | 26.72 | 18.90 | 19.99 |
| Cash & bank balances | 1.20 | 17.77 | 1.19 | 1.33 | 1.34 | 2.32 | 3.45 |
| Loans & advances | 3.99 | 9.60 | 9.14 | 10.04 | 11.52 | 11.42 | 11.08 |
| Total current assets | 22.88 | 70.84 | 71.74 | 74.24 | 78.95 | 63.37 | 54.24 |
| Total current liabilities | 20.66 | 66.36 | 37.92 | 33.83 | 44.53 | 24.70 | 21.39 |
| Net working capital | 2.22 | 4.48 | 33.82 | 40.41 | 34.42 | 38.67 | 32.85 |
| Total assets | 40.26 | 89.17 | 123 | 126 | 120 | 131 | 133 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 17.77 | 1.19 | 1.33 | 1.34 | 2.32 | 3.45 | 2.42 |
| Net cash from operating activities | (1.47) | 20.75 | 11.76 | 4.84 | 8.58 | 5.93 | (7.31) |
| Net cash from investing activities | 13.27 | (0.25) | (1.46) | 2.55 | 1.40 | 2.71 | (27.44) |
| Net cash from financing activities | (28.37) | (3.92) | (10.44) | (7.41) | (10.96) | (9.78) | 35.78 |
| Net change in cash | (16.57) | 16.58 | (0.14) | (0.01) | (0.98) | (1.13) | 1.03 |
| Closing cash | 1.20 | 17.77 | 1.19 | 1.33 | 1.34 | 2.32 | 3.45 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -8.1% | -50.1% | -10.1% | -11.9% | +5.6% | +29.2% | - |
| EBITDA growth | -7.8% | -269.2% | -14.7% | +202.8% | -63.6% | +61.8% | - |
| PBT growth | +10.8% | - | -97.5% | +9998.0% | - | +9998.0% | +9997.0% |
| Net income growth | +26.7% | -1715.3% | -56.2% | +135.6% | -6912.5% | +102.1% | - |
| Revenue CAGR (3Y) | -25.6% | -26.6% | -5.8% | +6.3% | - | - | - |
| EBITDA CAGR (3Y) | - | - | -2.0% | +21.3% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | -82.3% | -84.3% | +1.4% | +3.0% | -7.1% | +0.1% | -6.6% |
| Return on capital employed | - | 0.0% | +4.7% | +6.6% | 0.0% | +6.6% | 0.0% |
| Return on net worth | - | 0.0% | +1.3% | +3.4% | 0.0% | +0.1% | 0.0% |
| Debt / equity | - | 1.22 | 1.01 | 1.10 | 1.18 | 1.23 | 1.25 |
| Long-term debt / equity | - | 0.38 | 0.49 | 0.60 | 0.67 | 0.72 | 0.79 |
| Interest cover | -0.91 | -13.14 | 106.95 | 83.33 | 32,750.00 | 95.08 | 255.12 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.44 | 0.88 | 0.98 | 1.28 | 1.42 | 1.12 |
| Inventory turnover | - | 0.92 | 1.59 | 1.80 | 2.22 | 2.92 | 2.90 |
| Debtors turnover | - | 1.63 | 2.64 | 2.59 | 3.41 | 3.79 | 2.86 |
| EPS (₹) | (9.32) | (10.39) | 0.34 | 0.81 | (2.21) | 0.02 | (1.62) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 12.95 | 23.34 | 23.00 | 22.19 | 24.92 | 24.90 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 28.30 | 30.88 | 58.75 | 67.56 | 64.10 | 72.38 | 57.05 |
| Revenue growth | -8.4% | -47.4% | -13.0% | +5.4% | -11.4% | +26.9% | - |
| Other income | 1.16 | 0.25 | 1.06 | 0.65 | 0.48 | 0.21 | 0.80 |
| Total expenses | 48.03 | 46.03 | 51.18 | 58.58 | 59.14 | 63.07 | 49.42 |
| Employee cost | 0.00 | 6.51 | 7.18 | 7.76 | 7.72 | 6.44 | 3.96 |
| EBITDA | (19.73) | (15.15) | 7.57 | 8.98 | 4.96 | 9.31 | 7.63 |
| EBITDA margin | -69.7% | -49.1% | +12.9% | +13.3% | +7.7% | +12.9% | +13.4% |
| Depreciation | 2.13 | 2.61 | 3.68 | 3.64 | 2.57 | 2.45 | 2.45 |
| Interest | 0.21 | 2.16 | 4.93 | 4.79 | 5.25 | 6.40 | 5.90 |
| Profit before tax | (20.91) | (19.67) | 0.02 | 1.20 | (2.38) | 0.67 | 0.08 |
| Tax | 0.11 | (0.02) | (0.38) | 0.12 | (0.10) | 0.34 | 0.15 |
| Net profit | (7.79) | (7.41) | 0.40 | 1.05 | (2.21) | 0.41 | (0.14) |
| Net profit margin | -27.5% | -24.0% | +0.7% | +1.6% | -3.5% | +0.6% | -0.3% |
| EPS (₹) | (8.41) | (7.86) | 0.16 | 0.43 | (0.91) | 0.14 | (0.03) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | 23.36 | 23.36 |
| Reserves & surplus | (4.39) | 17.16 | 36.82 | 36.43 | 35.35 | 36.51 | 36.19 |
| Shareholders' funds (net worth) | 20.61 | 42.16 | 61.82 | 61.43 | 60.35 | 59.87 | 59.55 |
| Secured loans | 0.00 | 32.49 | 33.74 | 39.18 | 38.66 | 44.20 | 45.27 |
| Unsecured loans | 13.67 | 7.50 | 7.27 | 3.53 | 4.42 | 5.10 | 5.95 |
| Total debt | 13.67 | 39.99 | 41.01 | 42.71 | 43.08 | 49.30 | 51.22 |
| Total liabilities | 37.13 | 83.77 | 112 | 111 | 105 | 111 | 112 |
| Assets | |||||||
| Gross block | 48.68 | 47.85 | 48.41 | 48.27 | 48.03 | 31.37 | 30.36 |
| Net block | 22.01 | 23.32 | 25.88 | 29.42 | 32.83 | 18.73 | 20.77 |
| Capital work in progress | 6.16 | 15.07 | 14.70 | 13.89 | 13.00 | 25.71 | 24.80 |
| Investments | 2.20 | 7.09 | 7.09 | 7.09 | 7.09 | 7.09 | 7.09 |
| Inventories | 4.59 | 25.62 | 37.68 | 34.81 | 34.02 | 25.71 | 19.72 |
| Sundry debtors | 9.12 | 15.54 | 18.30 | 23.54 | 18.26 | 18.54 | 19.95 |
| Cash & bank balances | 1.13 | 17.66 | 0.73 | 1.13 | 1.22 | 2.21 | 3.02 |
| Loans & advances | 2.54 | 8.15 | 8.05 | 8.77 | 15.29 | 11.22 | 8.87 |
| Total current assets | 17.38 | 66.97 | 64.76 | 68.25 | 68.79 | 57.68 | 51.56 |
| Total current liabilities | 10.04 | 57.98 | 30.44 | 28.18 | 33.78 | 22.13 | 20.98 |
| Net working capital | 7.34 | 8.99 | 34.32 | 40.07 | 35.01 | 35.55 | 30.58 |
| Total assets | 37.13 | 83.77 | 112 | 111 | 105 | 111 | 112 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 17.66 | 0.73 | 1.13 | 1.22 | 2.21 | 3.02 | 2.33 |
| Net cash from operating activities | (1.53) | 20.66 | 6.94 | 2.15 | 5.51 | 5.46 | (9.24) |
| Net cash from investing activities | 13.36 | (0.27) | (0.93) | (1.08) | (3.85) | (1.20) | (25.16) |
| Net cash from financing activities | (28.36) | (3.46) | (6.41) | (1.17) | (2.65) | (5.07) | 35.09 |
| Net change in cash | (16.53) | 16.93 | (0.40) | (0.10) | (0.99) | (0.81) | 0.69 |
| Closing cash | 1.13 | 17.66 | 0.73 | 1.13 | 1.22 | 2.21 | 3.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -8.4% | -47.4% | -13.0% | +5.4% | -11.4% | +26.9% | - |
| EBITDA growth | -30.2% | -300.1% | -15.7% | +81.1% | -46.7% | +22.0% | - |
| PBT growth | -6.3% | - | -98.3% | +9998.0% | - | +737.5% | -91.4% |
| Net income growth | -5.1% | -1952.5% | -61.9% | +147.5% | -639.0% | +392.9% | - |
| Revenue CAGR (3Y) | -25.2% | -21.6% | -6.7% | +5.8% | +0.9% | +3.2% | +2.5% |
| EBITDA CAGR (3Y) | - | - | -6.7% | +5.6% | -14.2% | -10.5% | -8.9% |
| Profitability & leverage | |||||||
| Net income margin | -74.3% | -63.6% | +0.7% | +1.6% | -3.6% | +0.5% | -0.1% |
| Return on capital employed | - | 0.0% | +4.4% | +5.5% | 0.0% | +6.5% | +6.6% |
| Return on net worth | - | 0.0% | +0.6% | +1.8% | 0.0% | +0.7% | -0.3% |
| Debt / equity | - | 0.78 | 0.68 | 0.70 | 0.77 | 0.84 | 1.23 |
| Long-term debt / equity | - | 0.15 | 0.23 | 0.27 | 0.32 | 0.36 | 0.58 |
| Interest cover | -0.96 | -12.16 | 126.74 | 89.70 | 219.67 | 93.29 | 113.90 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.86 | 1.22 | 1.40 | 1.62 | 2.35 | 1.85 |
| Inventory turnover | - | 0.98 | 1.62 | 1.96 | 2.15 | 3.19 | 3.20 |
| Debtors turnover | - | 1.83 | 2.81 | 3.23 | 3.48 | 3.76 | 2.71 |
| EPS (₹) | (8.41) | (7.86) | 0.16 | 0.43 | (0.91) | 0.14 | (0.03) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 16.86 | 24.73 | 24.57 | 24.14 | 25.62 | 25.48 |
To see the full year-wise statements and ratios of Cian Healthcare Limited, buy the company report.
Board of directors of Cian Healthcare Limited
Cian Healthcare has 5 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Manish Goswami Also directs: Ananta Medicare Limited, Brahmoushadhi Sukham Private Limited | Director | 09 Jan 2026 | 0 Years 10 Months | Current |
| Anjani Misra Also directs: Ananta Medicare Limited | Director | 09 Jan 2026 | 0 Years 10 Months | Current |
| Pradeep Kumar Jain Also directs: Ananta Medicare Limited | Director | 09 Jan 2026 | 0 Years 10 Months | Current |
| Rajesh Jain | Managing Director | 09 Jan 2026 | 0 Years 10 Months | Current |
| Simmi Soni Also directs: Orex Impex Private Limited | Director | 16 Mar 2026 | 0 Years 7 Months | Current |
Peer comparison
Cian Healthcare Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Thinq Pharma-Cro Limited | ₹62.89 Cr (FY 2025) | 17.0% | Mumbai, Maharashtra, India | |||
| Preet Remedies Limited | ₹62.83 Cr (FY 2025) | 18.0% | Chandigarh, India | |||
| Sri Gayathri Drugs Private Limited | ₹62.48 Cr (FY 2025) | 15.0% | Hyderabad, Telangana, India | |||
| Shamshree Lifesciences Limited | ₹62.27 Cr (FY 2025) | 10.0% | Chandigarh, India | |||
| Enanti Labs Private Limited | ₹62.07 Cr (FY 2025) | -14.0% | Hyderabad, Telangana, India | |||
| MDC Pharmaceuticals Limited | ₹61.89 Cr (FY 2024) | 14.0% | Chandigarh, India | |||
| DNV Overseas Impex Private Limited | ₹61.67 Cr (FY 2018) | 74.0% | New Delhi, Delhi, India | |||
| Unijules Life Sciences Limited | ₹61.64 Cr (FY 2018) | -4.0% | Nagpur, Maharashtra, India | |||
| Cian Healthcare Limitedthis company | ₹28.3 Cr (FY 2026) | -₹10.06 Cr | -35.5% | -8.1% | 117 | Pune, Maharashtra, India |
To see the full peer comparison of Cian Healthcare Limited, buy the company report.
Auditor
Cian Healthcare Limited is audited by Agarwal Mahesh K. & Co. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Agarwal Mahesh K. & Co. | FY 2023 | 008007C |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 95.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 5.00%.
Sep 2026
QUARTER
95.00% Promoters
5.00% Retail & Others
Promoter holding - history
Now 95.00% · Sep 2026High 95.00% · Sep 2026Low 27.10% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 95.00% | 27.10% | 27.10% | 27.10% |
| Public | 5.00% | 72.90% | 72.90% | 72.90% |
Charges & borrowings
Open charges
None
Satisfied charges
₹60.53 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 24 Jun 2011 | 10300740 | Cholamandalam Investment and Finance Company Limited | ₹2.5 Lakh | Satisfied | |
| 16 Sep 2009 | 10183839 | Idbi Bank Limited | ₹60.5 Cr | Satisfied |
To see the full charge records of Cian Healthcare Limited, buy the company report.
Total charge records: 2 View all charges
Deals & funding
Cian Healthcare Limited has 47 deals on record (46 market trades, 1 ipo); the latest was in December 2025.
Total deals
47
Market trades
46
IPO
1
Deals on record (5 of 47)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2025 | Market trade | ₹8.1 Lakh | Buyer: Raj Breeders and Hatcheries Private Limited |
| Oct 2024 | Market trade | ₹6.6 Lakh | Seller: Sahi Logistics & Infra Private Limited |
| Sep 2024 | Market trade | ₹32.4 Lakh | Buyer: an individual Seller: Multiplier Share and Stock Advisors Private Limited , 2 individuals |
| Sep 2024 | Market trade | ₹9.6 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited |
| Jan 2024 | Market trade | ₹45.1 Lakh | Buyer: an individual Seller: Indiacredit Risk Management LLP |
To see the full deal history of Cian Healthcare Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Cian Healthcare Limited has 203 court cases on record: 67 filed by Cian Healthcare, 136 filed against it. 105 cases are pending and 98 are disposed.
Total cases
203
Filed by the company
67
Filed against the company
136
Pending
105
Disposed
98
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 180 | 129 | 94 |
| High courts | 22 | 6 | 11 |
| NCLT | 1 | 1 | 0 |
Cases on record (5 of 203)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary Case) | Filed against the company by Aarti Pharmalabs Limited | Pending |
| High Court of Gujarat | Court case (CR.MA) | Filed by the company against Solisom Healthcare LLP Thro Kirankumar Ganpatbhai Rangapadiya and 1 other | Pending |
| District court, Mumbai City Civil Court, Maharashtra | Commercial matter | Filed against the company by Anuh Pharma Limited A Public Limited Company, Through Its Authorized Representative Mr Suresh Kaki | Pending |
| District court, Pune, Maharashtra | Civil suit | Filed against the company by HDFC Bank Ltd Through Amarjit Pandekar | Pending |
| High Court of Gujarat | Court case (CR.MA) | Filed by the company against M/S Century Pharmaceuticals Limited Through Balkrishna Shetty and 1 other | Pending |
To see the full case history of Cian Healthcare Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Cian Healthcare Limited was last rated by Brickwork on 12 Nov 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Brickwork | 12 Nov 2020 |
To see the full credit ratings and regulatory alerts of Cian Healthcare Limited, buy the company report.
MSME payment delays
Cian Healthcare Limited has 22 MSME Form 1 returns on record between 2018 and 2024, listing 5,121 overdue payments to 198 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 198)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Herbo Nutra Extract Private Limited | |||
| an individual supplier | |||
| Syscom Packaging Company | |||
| Rashi Cooling Towers Private Limited |
To see the full MSME payment records of Cian Healthcare Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Cian Healthcare has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
1
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Dr. Smiths Biotech Private Limited | U24246PN2015PTC154818 |
To see the full group structure of Cian Healthcare Limited, buy the company report.
Employees & EPFO
Cian Healthcare Limited has a workforce of 117 employees on its EPFO records as of May 2026, across 2 active EPFO establishments.
Employee count
117
Active EPFO establishments
2
Employee growth
0.9%
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 117 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 |
To see the full employee and EPFO history of Cian Healthcare Limited, buy the company report.
GST
Cian Healthcare has 6 GST registrations: 2 active and 4 cancelled or inactive.
Total GSTINs
6
Active
2
Cancelled / inactive
4
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 05AACCC5027C1ZB | Uttarakhand | Active | 01 Jul 2017 |
| 27AACCC5027C1Z5 | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Cian Healthcare Limited, buy the company report.
Recent activity
Cian Healthcare Limited has 45 board changes on record since 2003: 25 appointments and 20 cessations. The latest: Simmi Soni was appointed as Director on 16 Mar 2026.
Filing
Cian Healthcare Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Pune.
Appointed
Simmi Soni was appointed as Director.
Charges
A charge registered on 16 Sep 2009 via Charge ID 10183839 with Idbi Bank Limited was fully satisfied on 29 Jan 2026.
Appointed
Anjani Misra was appointed as Director.
Appointed
Manish Goswami was appointed as Director.
Appointed
Pradeep Kumar Jain was appointed as Director.
Appointed
Rajesh Jain was appointed as Managing Director.
AGM
Cian Healthcare Limited last Annual general meeting of members was held on 17 Dec 2025 as per latest MCA records.
Ceased
Riyaz Bashir Khan ceased to be CFO.
Ceased
Munjaji Purbhaji Dhumal ceased to be Company Secretary.
Ceased
Paresh Arun Shah ceased to be Director.
Ceased
Swati Maheshwari ceased to be Director.
41 earlier events are in the company report.
News
Frequently asked questions
Cian Healthcare is an active public limited company based in Pune, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 07 January 2003 (23+ years old) and is registered under CIN L24233PN2003PLC017563. Listed on BSE: 542678.
Cian Healthcare reported revenue of ₹28.3 Cr for FY 2025-26 (down 8.1% YoY) based on consolidated financials.
Cian Healthcare has 5 current directors:
- Rajesh Jain - Managing Director
- Manish Goswami - Director
- Anjani Misra - Director
- Pradeep Kumar Jain - Director
- Simmi Soni - Director
The latest financial statements of Cian Healthcare on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 17 December 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Cian Healthcare is 05AACCC5027C1ZB, registered in Uttarakhand. The company has 6 GST registrations in all, of which 2 are active and 4 are cancelled or inactive. Other active GSTINs include 27AACCC5027C1Z5 (Maharashtra).
The CIN (Corporate Identification Number) of Cian Healthcare is L24233PN2003PLC017563. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Cian Healthcare is a listed company as per MCA records. Its shares are listed on BSE (code: 542678).
Cian Healthcare has 203 court cases on record: 67 filed by the company and 136 filed against it. 105 are pending. Most are in the district courts.
Cian Healthcare was incorporated on 07 January 2003, making it 23+ years old. It is registered with the Registrar of Companies, Pune.
Cian Healthcare has 47 deals on record (46 market trades, 1 ipo); the latest was in December 2025.
The peers of Cian Healthcare by revenue are Thinq Pharma-Cro Limited, Preet Remedies Limited, Sri Gayathri Drugs Private Limited, Shamshree Lifesciences Limited, Enanti Labs Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Simmi Soni was appointed as Director on 16 Mar 2026. Anjani Misra was appointed as Director on 09 Jan 2026. Manish Goswami was appointed as Director on 09 Jan 2026. Cian Healthcare has 45 board changes on record in total.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages